Mathias Vormehr
Overview
Explore the profile of Mathias Vormehr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
5369
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lopez J, Powles T, Braiteh F, Siu L, LoRusso P, Friedman C, et al.
Nat Med
. 2025 Jan;
31(1):152-164.
PMID: 39762422
Effective targeting of somatic cancer mutations to enhance the efficacy of cancer immunotherapy requires an individualized approach. Autogene cevumeran is a uridine messenger RNA lipoplex-based individualized neoantigen-specific immunotherapy designed from...
2.
Beck J, Diken M, Suchan M, Streuber M, Diken E, Kolb L, et al.
Cancer Cell
. 2024 Aug;
42(8):1467-1470.
PMID: 39137730
No abstract available.
3.
Peters D, Kranz L, Eisel D, Diken M, Kreiter S, Tureci O, et al.
Cancer Immunol Res
. 2024 Jun;
12(10):1409-1420.
PMID: 38885358
Interleukin 2 (IL-2) is a crucial cytokine in T-cell immunity, with a promising potential in cancer vaccines. However, therapeutic application of IL-2 is hampered by its short half-life and substantial...
4.
Beck J, Diken M, Suchan M, Streuber M, Diken E, Kolb L, et al.
Cancer Cell
. 2024 Mar;
42(4):568-582.e11.
PMID: 38490213
Major histocompatibility complex (MHC) class I antigen presentation deficiency is a common cancer immune escape mechanism, but the mechanistic implications and potential strategies to address this challenge remain poorly understood....
5.
Schrors B, Hos B, Yildiz I, Lower M, Lang F, Holtstrater C, et al.
Front Immunol
. 2023 Mar;
14:1102282.
PMID: 36969213
Introduction: The cell line MC38 is a commonly used murine model for colorectal carcinoma. It has a high mutational burden, is sensitive to immune checkpoint immunotherapy and endogenous CD8+ T...
6.
Muik A, Altintas I, Gieseke F, Schoedel K, Burm S, Toker A, et al.
Oncoimmunology
. 2022 Feb;
11(1):2030135.
PMID: 35186440
Immune checkpoint inhibitors (ICI) targeting the PD-1/PD-L1 axis have changed the treatment paradigm for advanced solid tumors; however, many patients experience treatment resistance. In preclinical models 4-1BB co-stimulation synergizes with...
7.
Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz L, Vormehr M, et al.
Nature
. 2021 May;
595(7868):572-577.
PMID: 34044428
BNT162b2, a nucleoside-modified mRNA formulated in lipid nanoparticles that encodes the SARS-CoV-2 spike glycoprotein (S) stabilized in its prefusion conformation, has demonstrated 95% efficacy in preventing COVID-19. Here we extend...
8.
Beck J, Reidenbach D, Salomon N, Sahin U, Tureci O, Vormehr M, et al.
Mol Cancer
. 2021 Apr;
20(1):69.
PMID: 33858437
Synthetic mRNA provides a template for the synthesis of any given protein, protein fragment or peptide and lends itself to a broad range of pharmaceutical applications, including different modalities of...
9.
Vogel A, Kanevsky I, Che Y, Swanson K, Muik A, Vormehr M, et al.
Nature
. 2021 Feb;
592(7853):283-289.
PMID: 33524990
A safe and effective vaccine against COVID-19 is urgently needed in quantities that are sufficient to immunize large populations. Here we report the preclinical development of two vaccine candidates (BNT162b1...
10.
Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz L, Vormehr M, et al.
Nature
. 2021 Jan;
590(7844):E17.
PMID: 33469214
No abstract available.